Sandoz Group (OTCMKTS:SDZNY) Stock Rating Lowered by UBS Group

Posted by on Feb 6th, 2025

UBS Group cut shares of Sandoz Group (OTCMKTS:SDZNY – Free Report) from a strong-buy rating to a hold rating in a report published on Monday,Zacks.com reports.

Separately, BNP Paribas downgraded shares of Sandoz Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 2nd.

View Our Latest Research Report on SDZNY

Sandoz Group Stock Up 4.1 %

Sandoz Group stock opened at $48.61 on Monday. Sandoz Group has a 12-month low of $27.79 and a 12-month high of $48.66. The firm’s fifty day moving average price is $43.52 and its 200 day moving average price is $43.20.

About Sandoz Group

(Get Free Report)

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.

Read More

Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.